Patients taking GLP-1 receptor agonists, such as Ozempic or Wegovy, face a 48% higher likelihood of developing smell or taste disturbances compared to those on other diabetes medications, according to a study published Thursday in JAMA Otolaryngology–Head & Neck Surgery. While the absolute risk remains low—affecting 0.37% of GLP-1 users versus 0.22% of non-users—researchers from the Hebrew University of Jerusalem suggest that clinicians monitor patients for sensory changes that could impact nutrition and quality of life.
How does the risk compare to other diabetes treatments?
Researchers analyzed medical records from over 170 health care centers globally to compare 439,000 type 2 diabetes patients taking GLP-1s against a matched group taking alternative diabetes drugs. The data revealed that despite the increased relative risk of 48%, the absolute occurrence of conditions like anosmia (smell loss), parosmia (distorted smell), or parageusia (distorted taste) is rare. This finding contrasts with earlier, smaller reports that suggested GLP-1s might actually enhance sensory perception in patients using the drugs specifically for weight management, indicating that the impact of these medications on sensory pathways may be highly complex.
Why should patients monitor their sensory health?
According to study co-author Nir Zontag, the primary concern is not an immediate health crisis but rather how these changes influence dietary behavior. If a patient experiences a distorted sense of taste or smell, it can alter food preferences and overall nutritional intake. Because the symptoms are often subtle, patients may not immediately link them to their medication. Early identification is vital because interventions like olfactory training—a form of physical therapy for the nose—have a higher success rate when started promptly after symptoms emerge.
What are the limitations of the current research?
The study, published in JAMA Otolaryngology–Head & Neck Surgery, is retrospective and observational, meaning it cannot definitively prove that GLP-1 medications cause these sensory disturbances. As Zontag noted, further clinical trials are necessary to clarify the biological mechanisms at play and to determine if specific drugs within the GLP-1 class carry different levels of risk. Until more specific data is available, the research team is not recommending that patients discontinue their prescribed treatment plans, but rather that they maintain open communication with their healthcare providers regarding any new sensory symptoms.
Frequently Asked Questions
- Should I stop taking my medication if I notice a change in taste? No. Researchers emphasize that the absolute risk is low and advise patients to consult their doctor rather than stopping treatment abruptly.
- What is olfactory training? It is a sensory therapy that involves repeatedly smelling specific scents to help retrain the brain and nasal pathways to recognize and process odors.
- Are these side effects permanent? The study does not conclude that these changes are permanent. Clinical awareness is encouraged so that potential recovery treatments can be initiated as soon as possible.
Have you experienced changes in your sense of smell or taste while on medication? Share your experience in the comments below or subscribe to our health newsletter for the latest medical research updates.
